Kunnathur Murugesan Sakthivel and Rajan Radha Rasmi (2025) Deciphering Novel Molecular Targets in Neuro-Oncology: An Update. Deciphering Novel Molecular Targets in Neuro-Oncology: An Update, 44 (4). pp. 81-96. ISSN 0731-8898

[thumbnail of 66. Kanisha JEPTO USA.pdf] Text
66. Kanisha JEPTO USA.pdf - Published Version
Download (5MB)

Abstract

Neuro-oncology is the study of brain and spinal cord neoplasms. Molecular targets and signaling pathways
are pivotal in advancing modern healthcare, particularly in personalized medicine. Signaling pathways, which regulate
cellular processes such as growth, division, and survival, are frequently dysregulated in cancer. Targeting these pathways
has enabled the development of personalized therapies that improve efficacy while minimizing side effects. This ap�proach has led to significant improvements in patient outcomes, reduced treatment toxicity, and a shift toward precision
medicine, driving innovation in drug discovery. The integration of molecular targets and signaling pathways into clinical
practice highlights their importance for enhancing patient care.

Item Type: Article
Uncontrolled Keywords: V. Ipatasertib (IPA) combined with non-taxane chemo�therapy (CT) for patients (pts) with previously treated advanced triple-negative breast cancer (aTNBC): The PATHFINDER phase IIa trial. 2024:1098. 94. Saxton RA, Sabatini DM. mTOR signaling in growth, me�tabolism, and disease. Cell. 2017;168(6):960–76. 95. Laplante M, Sabatini DM. mTOR signaling at a glance. J Cell Sci. 2009;122(20):3589–94. 96. Wang X, Proud CG. MTORC1 signaling: What we still don’t know. J Mol Cell Biol. 2011;3(4):206–20. 97. Ballesteros-Álvarez J, Andersen JK. MTORC2: The other mTOR in autophagy regulation. Aging Cell. 2021;20(8):e13431. 98. Fu W, Hall MN. Regulation of mTORC2 signaling. Genes. 2020;11(9):1045. 99. Anandappa G, Hollingdale A, Eisen T. Everolimus—A new approach in the treatment of renal cell carcinoma. Cancer Manag Res. 2010;2:61–70. 100. Rini BI. Temsirolimus, an inhibitor of mammalian target of rapamycin. Clin Cancer Res. 2008;14(5):1286–90. 101. Sehgal S. Sirolimus: Its discovery, biological prop�erties, and mechanism of action. Transplant Proc. 2003;35(3):S7–14. 102. Rivera VM, Squillace RM, Miller D, Berk L, Wardwell SD, Ning Y, Pollock R, Narasimhan NI, Iuliucci JD, Wang F, Clackson T. Ridaforolimus (AP23573; MK-8669), a potent mTOR inhibitor, has broad antitumor activity and can be optimally administered using intermittent dosing regimens. Mol Cancer Ther. 2011;10(6):1059–71. 103. Carballo GB, Honorato JR, de Lopes GP, Spohr TC. A highlight on Sonic hedgehog pathway. Cell Commun Sig�nal. 2018;16(1):11. 104. Lindström E, Shimokawa T, Toftgård R, Zaphiropoulos PG. PTCH mutations: Distribution and analyses. Hum Mutat. 2006;27(3):215–9. 105. Rubin LL, De Sauvage FJ. Targeting the Hedgehog path�way in cancer. Nat Rev Drug Discov. 2006;5(12):1026–33 106. Meiss F, Andrlová H, Zeiser R. Vismodegib. Recent Re�sults Cancer Res. 2018;211:125–39. 107. Jain S, Song R, Xie J. Sonidegib: Mechanism of action, pharmacology, and clinical utility for advanced basal cell carcinomas. Onco Targets Ther. 2017;1645–53. 108. Kim J, Tang JY, Gong R, Kim J, Lee JJ, Clemons KV, Chong CR, Chang KS, Fereshteh M, Gardner D, Reya T. Itraconazole, a commonly used antifungal that inhibits Hedgehog pathway activity and cancer growth. Cancer Cell. 2010;17(4):388–99. 109. Huveneers S, Phng L. Endothelial cell mechanics and dynamics in angiogenesis. Curr Opin Cell Biol. 2024;91:102441. 110. Ackermann M, Werlein C, Plucinski E, Leypold S, Kühnel MP, Verleden SE, Khalil HA, Länger F, Welte T, Mentzer SJ, Jonigk DD. The role of vasculature and angiogene�sis in respiratory diseases. Angiogenesis. 2024;27(3): 293–310. 111. Shaw P, Dwivedi SKD, Bhattacharya R, Mukherjee P, Rao G. VEGF signaling: Role in angiogenesis and beyond. Bio�chim Biophys Acta Rev Cancer. 2024;1879(2):189079. 112. Laviv Y, Regev O, Kanner AA, Fichman S, Limon D, Sie�gal T, Yust-Katz S, Benouaich-Amiel A. Stem the blood flow: Beneficial impact of bevacizumab on survival of subventricular zone glioblastoma patients. J Neurooncol. 2025 Jan;171(1):201–11. 113. Bressler SB, Barve A, Ganapathi PC, Beckmann K, Apte RS, Marcus DM, Baumane K, Agarwal S, Oleksy P, Re�ichstein DA, Patel SS. Aflibercept biosimilar myl-1701p vs reference aflibercept in diabetic macular edema: The INSIGHT randomized clinical trial. JAMA Ophthalmol. 2024;142(10):952–60. 114. Mongiardi MP, Pallini R, D’Alessandris QG, Levi A, Falchetti ML. Regorafenib and glioblastoma: A literature review of preclinical studies, molecular mechanisms and clinical effectiveness. Expert Rev Mol Med. 2024;26:e5. 115. Purow B, Fine HA. Progress report on the potential of an�giogenesis inhibitors for neuro-oncology. Cancer Invest. 2004;22(4):577–87. 116. Zhang AB, Mozaffari K, Aguirre B, Li V, Kubba R, Desai NC, Wei D, Yang I, Wadehra M. Exploring the past, pres�ent, and future of anti-angiogenic therapy in glioblastoma. Cancers. 2023;15(3):830. 117. Nowacka A, Śniegocki M, Smuczyński W, Bożiłow D, Ziółkowska E. Angiogenesis in glioblastoma—Treatment approaches. Cells. 2025;14(6):407. 118. Pellerino A, Bruno F, Soffietti R, Rudà R. Antiangiogenic therapy for malignant brain tumors: Does it still matter? Curr Oncol Rep. 2023;25(7):777–85
Divisions: PSG College of Arts and Science > Department of Biotechnology
PSG College of Arts and Science > Department of Biochemistry
Depositing User: Dr. B Sivakumar
Date Deposited: 05 Mar 2026 09:04
Last Modified: 05 Mar 2026 09:04
URI: https://ir.psgcas.ac.in/id/eprint/2682

Actions (login required)

View Item
View Item